SOURCE: Millennium Healthcare Inc.

Millennium Healthcare Inc.

June 03, 2015 12:30 ET

Millennium Healthcare Inc. Appoints Anthony Cataldo, CEO of Oxis Biotech, to Board of Advisors

MELVILLE, NY--(Marketwired - Jun 3, 2015) - Millennium Healthcare Inc. (OTCQB: MHCC), a healthcare services and medical device distribution company, today announced that the Company has appointed Anthony (Tony) Cataldo to the Board of Advisors effective June 1, 2015.

Mr. Cataldo is currently the Chairman and CEO of Oxis Biotech, Inc., and its parent company, Oxis International, Inc. (OTCQB: OXIS). Oxis is a biotechnology company focused on biotech cancer therapy development and commercialization. Prior to joining Oxis, Mr. Cataldo founded Genesis Biopharma, Inc., now known as Lion Biotechnologies, Inc. (LBIO). Mr. Cataldo created the highly successful Lion/Genesis (LBIO) with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. He has extensive experience in the biotechnology sector having served as Chairman and/or CEO of several biotech companies including: MultiCell Technologies, Inc., Calypte Biomedical Corporation, and Senetek, PLC. In addition to his extensive biotechnology experience, Mr. Cataldo has served in management positions with a number of emerging growth and publicly traded companies. Through his leadership of publicly traded companies, he has helped early-stage companies develop diverse businesses, improve market capitalization, attract investment capital, restructure operations and build infrastructures to support future growth.

Dominick Sartorio, Millennium's Chairman, stated, "We are proud to appoint Mr. Cataldo to our Board of Advisors. Millennium's recent growth has garnered increased interest in the Company from industry leaders and has afforded us the opportunity to broaden our leadership with senior industry executives such as Mr. Cataldo. We are honored to have him on board and look forward to his input in the coming months as we continue to move forward in our business plan."

Anthony Cataldo, Board of Advisors, added, "Millennium is becoming a leader in bringing non-invasive, early detection medical devices to the market, which are vital to the early diagnosis and treatment of life threatening diseases such as Melanoma. As the founder of Lion Biotechnologies, Inc. (LBIO), where I licensed Autologous Cell Therapy (ACT) technologies from the National Cancer Institute (NCI) specifically designed for the treatment of stage 4 Melanoma, I know only too well the results of what happens when a person has not had access to early detection. I look forward to being a part of Millennium's future."

About Oxis Biotech, Inc. (OXIS)

Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. OXIS' lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. For more information about Oxis Biotech, please visit http://www.oxis.com.

About Millennium Healthcare Inc. (www.millenniumhcs.net)

Millennium Healthcare Inc., through its wholly owned operating subsidiaries, provides primary care physician practices, physician groups and healthcare facilities of all sizes with cutting-edge medical devices focused primarily on preventive care through early detection. The Company also provides advanced billing and coding services, and practice development and management services. For more information, please visit www.millenniumhcs.net.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains certain statements that may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Forward-looking statements are identified by such words and phrases as "we expect," "expected to," "estimates," "estimated," "current outlook," "we look forward to," "would equate to," "projects," "projections," "projected to be," "anticipates," "anticipated," "we believe," "could be," and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. Because they are forward-looking, they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

Contact Information

  • CONTACT:

    JP Fortune Group
    James Moldenhauer
    949-218-4020